INP105

INP105 is a proprietary upper nasal formulation of olanzapine delivered using Impel Pharmaceuticals' Precision Olfactory Delivery (POD) technology. It is being developed for the rapid treatment of acute agitation and aggression associated with conditions such as autism spectrum disorder, bipolar I disorder, and schizophrenia. The device enables non-invasive administration by patients or caregivers, achieving peak plasma levels of olanzapine significantly faster than intramuscular injection or orally disintegrating tablets. This approach aims to provide a safe, effective alternative to injectable treatments for acute agitation outside hospital settings[1][2][3][4][5][6][7][8].

Other names

intranasal olanzapinePOD-olanzapine